ICER proposes changes to its assessments of Orphan drugs

The Institute for Clinical and Economic Review released an outline of proposed adaptations to its value framework to be applied in the assessment of Orphan drugs for serious ultra-rare conditions.

ICER said it would assess the cost-effectiveness of all new treatments that represent "a potential major advance for a serious ultra-rare condition." The group proposed using a broader range of incremental cost-effectiveness ratios in its analyses of willingness-to-pay thresholds, ranging from $50,000-$500,000 per quality-adjusted life year (QALY) for rare disease treatments. ICER plans to use its standard range of $100,000-$150,000 per QALY to calculate value-based price benchmarks...